Employing an unbiased immunopeptidome analysis of tumor specimens derived from 35 PDAC patients, VGLL1 was identified as a putative shared TAA, ranked second only to MUC16 in terms of tumor expression in comparison to essential normal tissues. Here, MUC16 is linked to neoplasm.